You have to ask yourself. Is the AFFY glass broken or does it just have a hole in its bottom?
2012 10K book value 22 cents/share. No revenue. No product. Probably half a dozen or fewer employees. Continuing expenses. Crushing litigation. 2012 10K disclosures: might not have enough litiation insurance coverage and bankruptcy certain unless Omontys quickly rehabilitated and introduced into market. Only asset is "blue sky" Takeda promise to pay milestone/royalties IF Omontys reintroduced to market. No unmet medical need served by Omontys where Epogen/Aranesp, with proven safety profiles, are industry standard. PEARL studies and actual patient usage prove Omontys unsafe. I'd say the glass is draining pretty fast to empty.